Infographic: Landmark trials in Neuro-Ophthalmology-results of the phase II Idiopathic Intracranial Hypertension Pressure Trial
- PMID: 40670630
- DOI: 10.1038/s41433-025-03918-8
Infographic: Landmark trials in Neuro-Ophthalmology-results of the phase II Idiopathic Intracranial Hypertension Pressure Trial
Conflict of interest statement
Competing interests: SM reports consultancy fees (Invex Therapeutics); advisory board fees (Ocular therapeutix); speaker fees (Teva); Travel (AbbVie and European Alliance of Associations for Rheumatology); Receipt of equipment (Heidelberg Engineering). SM is a section editor at Eye Journal. AS reports consultancy fees from Novartis, AbbVie, Vertex and Orion Pharma and speaker fees from Teva UK and Novartis. She was previously a Director and Chief Scientific Officer with shares at Invex Therapeutics. Authors declare no other financial relationships with any organisations that might have an interest in the submitted work; and no other relationships or activities that could appear to have influenced the submitted work.
References
-
- Mitchell JL, Lyons HS, Walker JK, Yiangou A, Grech O, Alimajstorovic Z, et al. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain. 2023;146:1821–30. https://doi.org/10.1093/brain/awad003 . - DOI - PubMed - PMC
-
- Mollan SP, Momin SNA, Khatkar PS, Grech O, Sinclair AJ, Tsermoulas G. A Neuro-Ophthalmologist’s Guide to Advances in Intracranial Pressure Measurements. Eye Brain. 2023;15:113–24. https://doi.org/10.2147/EB.S404642 . - DOI - PubMed - PMC
LinkOut - more resources
Full Text Sources